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SHPALL INSTALLED AS PRESIDENT;
GIRALT ELECTED VICE PRESIDENT
Elizabeth J. Shpall, MD, has been in-
stalled as President of the American
Society for Blood and Marrow Trans-
plantation. She is the Ashbel Smith
Professor of Medicine at the University
of Texas MD Anderson Cancer Center,
the Cell Therapy Laboratory medical
director, the Cord Blood Bank director,
and deputy chair, Department of
Stem Cell Transplantation and Cellular
Therapy.
Sergio A. Giralt, MD, chief of Adult
Bone Marrow Transplant (BMT) Ser-
vice at Memorial Hospital for Cancer
and Allied Diseases, chief of Adult
BMT Service at Memorial Sloan-
Kettering Cancer Center, and profes-
sor of medicine at Weill Cornell
Medical College is the newly elected
and installed Vice President, to be-
come president in 2014. Marco J.G.
de Lima, MD, director of the Depart-
ment of Stem Cell Transplantation
and Cellular Therapy Fellowship
Program, as well as the Matched Un-
related Donor Stem Cell Transplanta-
tion Program at the MD Anderson
Cancer Center in Houston, is the
newly elected and installed Treasurer.
The installation of new officers and
directors occurred at the Society’s an-
nual business meeting, the 2012
BMT Tandem Meetings, on Feb. 3 in
San Diego. The election was by ballot
among members of the Society in De-
cember and January.
Newly elected and installed direc-
tors are:
Corey S. Cutler, MD, MPH, of the
Dana-Farber Cancer Institute in
Boston, MA
John F. DiPersio, MD, PhD, of the
Washington University School of
Medicine in St. Louis, MO
Brenda M. Sandmaier, MD, of the
Fred Hutchinson Cancer Research
Center in Seattle, WA
All took office at the close of the
2012 BMT Tandem Meetings.C. Fred LeMaistre, MD, was ele-
vated to President-Elect and will as-
sume the Presidency in 2013. He is
the Physician in Chief, Hematology
and Bone Marrow Transplant, at the
Sarah Cannon Cancer Center.TWO NEW INVESTIGATORS WIN BBMT
EDITORIAL AWARDS
Two medical scientists are the recip-
ients of editorial awards for new inves-
tigators for their articles published in
2011 in Biology of Blood and Marrow
Transplantation.
Both are recipients of a $5,000
prize, supported by grants from STEM-
CELL Technologies Inc., and STEM-
SOFT Software Inc. Selection of the
winning articles was by the BBMT
Editorial Board and the ASBMT Publi-
cations Committee.
Brile Chung, PhD, is the winner
of the Ernest McCulloch & James Till
Award for best basic science article
by a new investigator. The award is
supported by an education grant
from STEMCELL Technologies Inc.
His article was ‘‘Combined Effects
Of IL-7 and SCF Administration
On Lymphopoiesis after Murine
Bone Marrow Transplantation.’’
Joseph A. Pidala, MD, is recipi-
ent of the George Santos Award for
best clinical science article by a new in-
vestigator. The award is supported by
an education grant from STEMSOFT
Software Inc. His article was ‘‘Varia-
tion In Management of Immune
Suppression after Allogeneic
Hematopoietic Cell Transplan-
tation.’’
The awards were presented by
ASBMT’s President, Daniel Weisdorf,
MD, during the 2012 BMT Tandem
Meetings in San Diego.SIX ABSTRACTS CHOSEN AS BEST OF
2012 BMT TANDEM MEETINGS
A total 553 abstracts from 31 coun-
tries were accepted for the 2012 BMT
Tandem Meetings.Six of the abstracts were selected
for awards by the Abstract Review
Committees.
Recipients of the ASBMT Best
Abstract Awards for Basic Science
Research were:
Leslie Kean, MD, PhD – RHESUS
MACAQUE NATURAL CD4 REGULA-
TORY T CELLS EXHIBIT DECREASED
PROLIFERATION BUT ENHANCED
SUPPRESSION AFTER PULSING WITH
SIROLIMUS
Michael Jordan, MD – GENE
THERAPY FOR HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS: FIXING A
CRITICAL ‘CIRCUIT BREAKER’ IN THE
IMMUNE SYSTEM
Mark Vander Lugt, MD –
PLASMA CONCENTRATION OF SUP-
PRESSOR OF TUMORIGENICITY 2
(ST2), THE IL33 RECEPTOR, AT INITIA-
TION OF GRAFT VERSUS HOST DIS-
EASE THERAPY PREDICTS DAY 28
RESPONSE AND DAY 180 SURVIVAL
POST-TREATMENT
Each received a $1,000 prize. The
clinical research awards are sup-
ported by a grant from HistoGenetics.
Recipients of the CIBMTR Best Ab-
stract Awards for Clinical Research
were:
ColleenDelaney,MD,MSc – IN-
FUSION OF NON-HLA MATCHED,
OFF-THE-SHELF EX VIVO EXPANDED
CORD BLOOD PROGENITOR CELLS
IN PATIENTS UNDERGOING MYELOA-
BLATIVE CORD BLOOD TRANSPLAN-
TATION IS SAFE AND DECREASES
THE TIME TO NEUTROPHIL RE-
COVERY
Francisco Marty, MD –
CMX001 FOR PREVENTION AND
CONTROL OF CMV INFECTION IN
CMV-SEROPOSITIVE ALLOGENEIC
STEM-CELL TRANSPLANT RECIPIENTS:
A PHASE 2 RANDOMIZED, DOUBLE-
BLIND, PLACEBO-CONTROLLED,
DOSE-ESCALATION TRIAL OF SAFETY,
TOLERABILITY AND ANTIVIRAL
ACTIVITY
Joseph Pidala, MD, MS –
OVERLAP SUBTYPE OF CHRONIC655
656 ASBMT NewsGVHD IS ASSOCIATED WITH
ADVERSE PROGNOSIS, FUNCTIONAL
IMPAIRMENT, AND INFERIORPATIENT REPORTED OUTCOMES: A
CHRONIC GVHD CONSORTIUM
STUDYEach also received a $1,000 prize.
The clinical research awards are sup-
ported by a grant from WellPoint, Inc.
